F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US) and Agilent Technologies, Inc. (US) are the Key Players in the Immunohistochemistry (IHC) Market
The global immunohistochemistry market is projected to reach USD 4.7 billion by 2028 from USD 3.2 billion in 2023, at a CAGR of 7.4% during the forecast period of 2023 to 2028. Factors such as rising geriatric population and growing prevalence of cancer diseases, technological advancements in IHC, the availability of reimbursement for IHC tests, and adoption of digital pathology are the major factors driving the growth of this market. However, the high degree of consolidation is expected to restrain the market’s growth during the forecast period. The product failures and recalls and lack of standardization may also pose a challenge to the growth of this market to a certain extent.
The global immunohistochemistry market is highly competitive. Prominent players operating in the global immunohistochemistry market include F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), and Agilent Technologies, Inc. (US). The key players in this market are increasingly focusing on strategic expansions, partnerships, and product launches and approvals to expand their product and geographic footprint and increase market presence.
To know about the assumptions considered for the study download the pdf brochure
F. Hoffmann-La Roche AG (Roche) is a global biotechnology company engaged in the development and manufacturing of pharmaceutical and diagnostic products. The company operates in the IHC market through the Pathology Lab segment which is a part of Diagnostics Division. The company provides a range of immunohistochemistry products such as BenchMark ULTRA IHC/ISH System, and OptiView DAB IHC Detection Kit (OptiView) through the Pathology Lab segment. Roche’s contribution to the IHC market through product launches has made it a prominent market player. The product launches also include both new products and improved products with an expanded application base. For instance, during the past five years, BenchMark ULTRA PLUS system, VENTANA DP 600 slide scanner, Elecsys anti-p53 Immunoassay, and VENTANA ALK (D5F3) CDx Assay have been added to its product portfolio, while product approvals were received for new Primary antibodies and VENTANA MMR RxDx systems for additional diseases applications. The company has a presence across Europe, the Middle East & Africa, North America, Asia Pacific, and Latin America.
Danaher Corporation (US) is a global science and technology company that designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company offers IHC products through its subsidiary Leica Biosystems, under the Anatomical Pathology Diagnostics and Core Lab Diagnostics segments. Danaher offers a wide range of chemical and immuno-staining instruments, reagents, and consumables. The company’s strong focus on a broad range of customers, technology-enabled solutions, investments in R&D, and comprehensive quality product lines are contributing to its growing market share. The company conducts R&D activities for the purpose of developing new products as well as enhancing the functionality, effectiveness, ease of use, and reliability of its existing products. The company’s R&D efforts include internal initiatives and those that use licensed or acquired technology, and it works with leading research institutions, universities, and clinicians around the world to develop, evaluate, and clinically test its products. For instance, the US patent grant for Leica Biosystems’ Real-time Focussing (RTF) technology was evaluated in the University of California (LA) for testing the technology. Also, the company carried out deals such as, In November 2022, Danaher subsidiary Leica Biosystems Nussloch GmbH acquired Cell IDx, Inc. an immunodiagnostic company offering chromogenic and fluorescent multiplex IHC biomarker profiling products such developments gain competitive advantage for Danaher in the IHC market.
Agilent Technologies, Inc. (US) is a leading player in life sciences, diagnostics, and applied chemical markets, providing application-focused solutions that include instruments, software, services, and consumables for the entire laboratory workflow in the fields of food, environmental and forensics, pharmaceutical, diagnostic, chemical & energy, and research. Agilent operates in the IHC market through Pathology Solutions, a subsegment of Diagnostics and Genomics segment. The company offers IHC products focused on cancer diagnostics and anatomic pathology workflows. In January 2023, Agilent signed a partnership del with Akoya Biosciences for developing chromogenic and immunofluorescent multiplex assays. These assays will be used for immunohistochemistry diagnostic solutions. The company is also focusing on continuous expansions in developed as well as developing regions. In 2022, the company established an Center for Excellence (CoE) in India to develop new products for analytical chemistry, biopharmaceuticals, and life science research. The company has a presence across North America, Europe, and Asia Pacific. Major countries include the US, the UK, Australia, China, Germany, Italy, Malaysia, Singapore, Belgium, Denmark, Japan, and the Netherlands.
Related Reports:
Immunohistochemistry (IHC) Market by Product (Antibodies, Reagents, Equipment, Kits), Application (Diagnostics [Cancer, Infectious, Autoimmune Diseases], Research, Forensic), End Users (Diagnostic laboratories, Research Institute) - Global Forecast to 2028
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]
This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.
SEND ME A FREE SAMPLE
